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Abstract
Head and neck malignancies are characterized by a multiphasic and multifactorial etiopathogenesis.
Tobacco and alcohol consumption are the most common risk factors for head and neck malignancy.
Other factors, including DNA viruses, especially human papilloma virus (HPV), may also play a role
in the initiation or development of these lesions. The pathways of HPV transmission in the head
and neck mucosal lesions include oral-genital contact, more than one sexual partner and perinatal
transmission of HPV to the neonatal child. The increase in prevalence of HPV infection in these
lesions may be due to wider acceptance of oral sex among teenagers and adults as this is perceived
to be a form of safe sex. The prevalence of HPV in benign lesions as well as malignancies has been
assessed by many techniques. Among these, the polymerase chain reaction is the most sensitive
method. Review of literature reveals that HPV may be a risk factor for malignancies, but not in all
cases. For confirmation of the role of HPV in head and neck squamous cell carcinoma, large
population studies are necessary in an assortment of clinical settings. Prophylactic vaccination
against high-risk HPV types eventually may prevent a significant number of cervical carcinomas. Of
the two vaccines currently available, Gardasil® (Merck & Co., Inc.) protects against HPV types 6,
11, 16 and 18, while the other vaccine, Cervarix® (GlaxoSmithKline, Rixensart, Belgium) protects
against HPV types 16 and 18 only. However, the HPV vaccine has, to the best of our knowledge,
not been tried in head and neck carcinoma. The role of HPV in etiopathogenesis, prevalence in
benign and malignant lesions of this area and vaccination strategies are briefly reviewed here.
Background
Head and neck squamous cell carcinoma (HNSCC) is a
significant cause of cancer worldwide [1]. Incidence rates
of these malignancies have been rising in most regions of
the world. It is estimated that 35,310 (25,310 males and
10,000 females) new cases of oral cavity & pharyngeal
malignancies will be diagnosed in the US during 2008,
while 7,590 (5,210 males and 2,380 females) patients will
die of the disease [2]. The authors reported that oral and
oropharyngeal malignancies were commonest in men in
North India and accounts for about 30–40% of all cancer
types in India making it a leading cause of cancer mortal-
ity [3-5]. The term "head and neck cancer" has been
widely adopted in the recent literature and includes
lesions at several anatomical sites: lip, oral cavity, nose
and paranasal sinuses, nasopharynx, oropharynx,
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hypopharynx, and larynx [6]. They are characterized by a
multiphasic and multifactorial etiopathogenesis [7-9].
Tobacco and alcohol consumption are the most common
risk factors for HNSCC [10]. In addition, Bosh et al
reported that approximately 15% of all malignancies
worldwide appear to be connected with viral infections
and several human DNA viruses are now accepted as caus-
ative factors [11]. Majority of the head and neck malig-
nancies originate from the epithelium which lines the
upper aerodigestive tract i.e., the oral cavity, pharynx and
larynx [12,13]. The epithelial areas of the upper aero-
digestive tract display greatest susceptibility to HPV due to
the easy exposure of the basal cells to HPV infection [14].
The pathways of HPV transmission in the mucosal lesion
may be oral-genital contact by kissing and oral sex, more
than one sexual partner and perinatal transmission of
HPV to the neonatal child [15,16].
The participation of HPV in oral and oropharyngeal car-
cinogenesis was first proposed by Syrjanen et al in 1983
[17] and then supported by several other authors [18-21]
including Gillison et al who reported that the high-risk
human papillomavirus (HR-HPV) genotypes are involved
in a subset of HNSCC in their epidemiological and molec-
ular study [22].
Many detection methods have been used to study the role
of HPV virus, like in-situ hybridization (ISH), Immuno-
histochemistry (IHC), Southern Blotting, Polymerase
Chain Reaction (PCR), DNA micro-arrays and Hybrid
Capture-II (HC-II) high risk and low risk detection meth-
ods. In the PubMed database, the following keywords
were used for the literature survey: HPV detection meth-
ods, HPV in head and neck cancer, HPV in benign lesion,
premalignant and malignant lesion of head and neck,
HPV in oral pre-cancer, HPV in oral cancer, HPV in larynx,
HPV in Pharynx, Expression of HPV in OSMF, detection of
high risk HPV by PCR etc. The objective of this review is to
summarize the various techniques of detection and the
role of HPV in the etiology of benign, potentially malig-
nant and malignant lesions of head and neck.
Molecular structure and role of high and low risk HPV in 
HNSCC
Human Papilloma virus is about 55 nm in diameter. It has
a single circular double stranded DNA molecule and
belongs to the family papillomaviridae. Its genome is
made up of 7,200 – 8,000 base pairs with a molecular
weight of 5.2 × 106 D. On the basis of DNA base pair (bp)
distribution, the viral DNA is divided into three parts: first
a 4,000 bp region that responsible for viral DNA replica-
tion and cell transformation, second 3,000 bp region that
encodes the structural proteins of the virus particles and
last 1,000 bp non-coding region (NCR) that contains the
origin of viral DNA replication.
Zur et al suggested that the genomic HPV DNA has nine
open-reading frame sequences (ORFS) -present on single
strand of DNA and are divided into seven early (E) and
two late-phase genes (L). The transcription of viral DNA is
regulated by early phase gene, while the capsid proteins
(involved in viral spread) are regulated by late phase gene
[23]. The early-phase gene (E) encodes the E1, E2, E5, E6,
and E7 proteins. E1 and E2 gene products regulated the
transcription and replication of viral proteins and E5 gene
product transcribed from the episomal region of the viral
DNA [24]. The E6 and E7 oncoprotiens are usually under
control of E1 and E2 inhibitory genes. These genes have
the ability to de-stimulate the tumor suppressor function
and regulate the functions of the p21, p53, and pRb pro-
teins, resulting in apoptosis, DNA repair and cell cycle
control and may finally lead to cellular immortalization.
(Fig. 1) The non-coding, long control region (LCR) con-
tains binding sites for the E1 and E2 gene products,
located just upstream of the promoter sequence 97 (P 97)
which controls the transcription of the E6 and E7 onco-
genes [25].
HPV must adhere to a specific receptor protein on the
keratinocytes membrane. Once the virus entered into the
cell, it transforms itself of its protein coat and the viral
DNA may then utilize host cell themselves. These viruses
elaborate early gene proteins (E) that are able to regulate
the host cell cycle, or mitotic capabilities. The E6 and E7
proteins are most important in this respect; they bind two
host proteins that are regulators of the keratinocytes at the
time of cell division. E6 binds to a protein designated p53,
a molecule that arrests cell division. However, once
bound, it is degraded and this inhibition of keratinocytes
mitosis is abrogated. Likewise, E7 binds a protein termed
Rb; and, similarly, cell cycle regulation is troubled.
On the basis of their genotype, more than 120 types of
HPV viral DNA genotypes have been fully sequenced
[26,27]. It classified on the bases of their infection in epi-
thelial cells and the ability to effect cellular transforma-
tion for e.g. HPV 1 is responsible for the infection in
cutaneous cell while HPV 6, 11, 18 for mucosal epithelial
cells of the oral cavity, oropharynx, anogenital tract and
uterine cervix [28]. The potentially oncogenic HPV is
divided into high and low-risk types. The high-risk HPV
such as 16, 18, 31, 33, 35, 52, 58, 59, 68, 73, and 82 are
responsible for malignancies while the low-risk sub types
(6, 11, 40, 42, 43, 44, 54, 61, 70, 72 and 81) are rarely
found in carcinoma and frequently connected with
benign and potentially malignant lesions of the head and
neck.Head & Neck Oncology 2009, 1:22 http://www.headandneckoncology.org/content/1/1/22
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Although HNSCC is closely linked to tobacco and alcohol
use, there is an increasing incidence HPV16-related
HNSCC arising in the oropharynx [29,22,30,31]. Bouda
et al suggested that high risk HPV E6/E7 transcripts and
viral integration have also been detected in HNSCC. Tran-
scriptionally active HR-HPVs, particularly HPV-16, are
found in a subset of HNSCC. HPV16-associated carcino-
genesis is mediated by expression of the viral E6 and E7
oncoproteins, which cause deregulation of the cell cycle
by inactivating p53 and pRb respectively [26]. HNSCC
with transcriptionally active HPV16 DNA are character-
ized by occasional chromosomal loss, whereas HNSCCs
lacking HPV DNA are characterized by gross deletions that
involve whole or large parts of chromosomal arms and
that already occur early in HNSCC development. These
distinct patterns of genetic alterations suggest that HPV16
infection is an early event in HNSCC development [32].
Chen et al suggested that the combined variants of p53
and p73 significantly increase the risk of HPV16-associ-
ated oral cancer, especially among never-smokers [33]. In
another report, they studied the p73 G4C14-to-A4T14
polymorphism may modulate the risk of HPV-16-associ-
ated oropharynx squamous cell carcinoma (SCCOP) and
the p73 variant genotypes may be markers of genetic sus-
ceptibility to HPV-16-associated SCCOP, particularly in
never smokers and never drinkers [34]. Ji et al reported
that p73 polymorphism was connected with HPV-16 in
HNSCC and may serve as a marker of positive HPV-16
tumor in patients with HNSCC, in oropharyngeal cancer
[35]. Li et al suggested that this p73 polymorphism may
be a risk marker for genetic susceptibility to HNSCC [36].
Pintos et al reported that HPV 16 was identified in tonsil-
related cancers. [37]. HPV has been found to be the most
significant positive prognostic factor in patients with
oropharyngeal tumors, with a 60–80% reduction in the
risk of death [38]. HPV positivity designates a specific sub-
group of oropharyngeal squamous cell carcinomas that
arise preferentially among individuals with no consump-
tion of tobacco and alcohol and that have a favorable out-
come attributable to an increased sensitivity toward
radiotherapy [39].
Detection Techniques
Pathological Examination
Cytological and Histopathological Examination
Different methods are used to detect specific types of HPV
DNA in lesions and shows varying sensitivity and specifi-
Mechanisms of HPV-associated oral carcinogenesis Figure 1
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city [40]. The detection of HPV in the oral mucosa may be
done by cytology and histological examination. On the
basis of cytology and histopathology, HPV infection is
characterized by koilocytosis, perinuclear cytoplasmic
haloes, nuclear dysplasia, atypical immature metaplasia
and binucleation. (Fig. 2) These methods show limited
sensitivity and are unable to determine which types of
HPV are involved in the infection of the epithelial cells.
Smith et al suggested that oral scrapes or rinse samples,
with their greater surface area of mucosa than with biop-
sies, are less invasive, and high risk HPV detection in oral
exfoliated cells is a reliable biomarker of an HPV-related
head and neck cancer risk. A drawback is that not all
patients who have HR-HPV types in oral exfoliated cells
are detected with HPV DNA in the primary tumour [31].
In situ hybridization (ISH) and immunohistochemistry
In situ hybridization (ISH) techniques employ the use of
type-specific radioactively labeled DNA probes, which are
complementary to HPV DNA sequences used for detec-
tion of viruses in the premalignant and malignant lesions
of the head and neck. ISH and immunohistochemistry
have low sensitivity because these tests only detect the
virus when it is present in more than 10 copies of the viral
DNA per cell. Lee et al studied the formalin-fixed, paraf-
fin-embedded tissue sections through in situ hybridiza-
tion using newly available probe sets and concluded that
the new probe sets for HPV can be used very efficiently in
clinical pathology material of HNSCC [41].
Molecular detection methods
Southern Blotting
Southern Blotting is an assay that has long been one of the
standard techniques for the detection of HPV DNA. This
blotting has the ability to differentiate between episomal
and integrated DNA and can detect up to 0.1 copy of viral
DNA per cell. This method has some technical variability
and requires a significant amount of DNA. Frazer and Kay
et al suggested that Southern blot may boast a theoreti-
cally higher specificity but is clearly less sensitive than
PCR [42,43]. Similarly; Gillison et al studied the Southern
blot and reported that, in non-oropharyngeal tumors, it
was rarely positive when compared with PCR. [22]. Yeu-
dall et al utilized both type-specific PCR and Southern
blot for HPV 16/18 and reported that there was a manifest
variation in the two techniques. Two of 39 oral carcinoma
samples were positive for either HPV 16/18 by Southern
blot, whereas 18/39 was positive by type specific PCR for
HPV 16/18. These studies evidently demonstrate the dif-
ference in sensitivity in these two assays. [44].
Polymerase chain reaction (PCR)
PCR is highly sensitive detection method for specific sub-
types of HPV because it detects the virus in less than 1
copy of the viral DNA per cell [45]. Universal primers of
conserved DNA sequences in HPV have been designed to
the L1 region i.e. MY09/MY11 [46], E1 region i.e. CPI and
CPII, E6 region and E7 region [47]. The majority of studies
used the primers MY09/11 for the detection of human
papilloma virus having base pair 450 bp responsible for
different types of cancers.
Quantitative PCR utilizes a fluorescent probe which helps
to measure the degree of fluorescence in the reaction mix-
ture. Ha et al reported the advantages of quantitative PCR
in premalignant and malignant lesions of the oral cavity
and analyzed the samples previously found to be HPV
positive by other molecular methods [21]. Termine et al
conducted a meta-analysis of studies (1988–2007) on
HPV in non site-specific HNSCC vs. OSCC biopsies and
found that the pooled prevalence of HPV DNA in the
overall samples was 34.5%, while it was 38.1% in OSCC
and 24.1% in the non site-specific HNSCC group [48].
Kreimer et al also studied the genotype frequency of HR-
HNSCC and reported that an overall prevalence of HPV in
25% in HNSCC, 35.6% in oropharyngeal cancer and
23.5% in OSCC [49].
Hybrid capture II (HC II)
The HC II technique is a nucleic acid hybridization assay
with signal amplification that utilizes microplate chemi-
luminescent detection. First, double stranded DNA is
denatured by using a strong alkaline denaturation solu-
tion that converts it into single stranded DNA (ssDNA).
This ssDNA is then hybridized in-solution to a cocktail of
specific 13 high risks HPV RNA probes. The resultant
DNA-RNA hybrids are captured onto the surface of a
micro-well plate coated with particular antibodies for
DNA-RNA hybrids. The immobilized hybrids are reacted
Squamous Epithelial layer showing koilocytosis Figure 2
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with alkaline phosphate conjugated antibody and
detected by cleavage of the chemiluminescent substrate.
The emitted light is measured as relative light unit (RLU)
in a luminometer. The intensity of the light is propor-
tional to the amount of target DNA in the sample. Speci-
mens with RLU greater than or equal to the mean of the
three positive control values are considered HPV positive.
Estimation of HPV Viral Load, a ratio of relative light unit
(RLU) of the sample to mean of RLU of the three positive
controls (PC), has been taken as estimate of approximate
viral load, which relates to the index of intensity of HPV
infection. This ratio of any specimen represents empiri-
cally a relative measure of its viral load. Cut off value (RLU
of specimen/mean RLU of PC) is 1.0 pg/ml of sample. The
hybridization method of HC II Digene® is approved by
Food and Drug Administration (FDA) USA for routine
clinical purposes. Detection of HPV DNA is carried out by
using probes of 13 high risks HPV genotypes (16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59 and 68).
Gene Expression: DNA Microarray
DNA microarray is a compilation of microscopic DNA
spots on a solid surface by covalent attachment to a chem-
ical matrix. Each gene on the solid supports referred to as
spot or probe is usually less than 200 μm in diameter.
Each spot has a unique sequence different from the others
in the array and will hybridize only to its complimentary
strand. This technique uses a DNA probe labeled with
either a radioisotope or a fluorescent tag. The probe is
applied to the fragment of DNA or RNA to be studied and
by the rules of base pairing (A to T, C to G) "sticks" to its
complementary sequence. This technology has made it
possible to miniaturize methods of probe detection for
DNA and allow detection of several thousand DNA or
RNA sequences in one experiment.
DNA microarrays have been successfully used to identify
global patterns of gene expression in different human
neoplasia, including head and neck cancers. [50]. Many
investigators have used microarrays to analyze gene
expression changes in HNSCC in tissues and cell lines, but
little is known about the gene expression changes in HPV
associated HNSCC [51-53]. The identification of molecu-
lar portrait of gene expression profiles in HPV-positive
and negative HNSCC, including their differences, could
result in a better understanding of critical events during
carcinogenesis.
Ivan et al compared the cellular gene expression profiles
of HPV-positive and negative in normal epithelium and
oropharyngeal carcinomas with the help of Affymetrix
Human U133A Gene Chip® and suggested the specific
expression of gene patterns in HPV-positive and HPV-neg-
ative oropharyngeal squamous carcinomas that may serve
as potential biomarkers for the development of HNSCC
[54]. DNA microarray technology is an exciting, rapidly
expanding biotechnological methodology and will hope-
fully enable both a greater understanding of the biology of
head and neck cancer and help in the clinical manage-
ment of this disease.
Prevalence of HPV in benign lesions of the Head and neck
Detection methods of HPV in benign lesions indicates
that not all types of viral infections can cause disease and
it would be essential to recognize the factors that deter-
mine its capability to induce malignant transformation in
head and neck lesions. Respiratory papillomatosis associ-
ated with human papilloma virus (HPV) infection is the
most common benign laryngeal neoplasm [55]. Laryngeal
papillomatosis is the most frequent benign neoplasia in
children and it is caused by HPV 6 and 11. The lesions are
exophytic and highly recurrent, compromising the airway
mucosa, mainly the larynx [56]. Juvenile laryngeal papil-
lomatosis is a rare condition caused by HPV [57]. DeVoti
et al reported that recurrent respiratory papillomas (RRP)
are benign airway tumors, caused primarily by HPV types
6 and 11 [58]. Castro et al reported the prevalence of HPV
6, 11 in normal oral mucous membrane. In oral benign
lesions associated with HPV, a prevalence of HPV 6 and
11 was observed in squamous cell papilloma (SCP) and
condyloma acuminatum, while HPV 2 and 57 were more
prevalent in verruca vulgaris lesions [59]. Fischer et al sug-
gested that the applied broad-spectrum PCR system is a
reliable tool in the detection of HPV DNA in benign
lesions of the upper aerodigestive tract [60]. Hoffmann et
al suggested that HPV is correlated to a lesser extent to
infectious mucosal lesions than to proliferative lesions.
Furthermore, the results emphasize that the presence of
HPV in specific lesions does not occur by chance, but rep-
resents a specific infection of the mucosa leading to pro-
liferation and even to malignancy [61]. (Table 1)
Prevalence of HPV in potentially malignant lesions of the 
Head and neck
Several investigators have studied the prevalence of HPV
in potentially malignant lesions, hoping to find a similar
HPV prevalence as in malignant diseases. An increasing
prevalence of HPV in premalignant lesions suggests that it
may play a role in malignant transformation. Ha et al
reported 1% prevalence of HPV 16 and 18 in premalig-
nant oral lesions by using the quantitative PCR. [21]. On
the other hand, Bagan et al did not find any association
between HPV DNA an PCR in proliferative verrucous leu-
koplakia (PVL) and HPV [62].
Furrer et al reported 41% HPV DNA detection by PCR-
Southern blot analysis in premalignant and malignant
lesions [63]. Ostwald et al studied the occurrence of DNA
of different subtypes of HPV 6/11, 16 and 18 detected byHead & Neck Oncology 2009, 1:22 http://www.headandneckoncology.org/content/1/1/22
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Table 1: Prevalence of HPV identification in benign lesions of the Head and neck
Study Year HPV type Mode of Detection Tumor Type
Fischer et al [60] 2005 Different HPV types Applied broad-spectrum PCR Benign lesions
Castro et al [59] 2006 6/11 Review Squamous cell papilloma
Martins et al [56] 2008 6 HPV typing (PCR), light microscopy and electron 
microscopy
Laryngeal papillomatosis
Förster et al [57] 2008 6/11 PCR Juvenile laryngeal papillomatosis
DeVoti et al [58] 2008 6/11 PCR, micro array Respiratory papillomas (RP)
Kovalenko et al[55] 2009 6/11 IHC Respiratory papillomatosis
Table 2: Prevalence of HPV identification in premalignant lesions of Head and Neck
Study Year Positive/cases % Lesion Type Mode of Detection
Zeuss et al [87] 1991 0/20 0 Dysplasia ISH 6/11, 16/18, 31/33/35
Holladay & Gerald [88] 1993 13/45 28.9 Dysplasia, inflammation hyperplasia E1 PCR
Fouret et al [89] 1995 0/3 0 Dysplasia E6 consensus PCR
Nielsen et al [90] 1996 20/49 40.8 Dysplasia leukoplakias ISH/HPV 16 PCR, SB PCR
Wen et al [91] 1997 5/17 29.4 Papilloma, leukoplakias, OLP E6 HPV 16/18 PCR
D'Costa et al [70] 1998 27/80 33.8 Leukoplakias, OLP, OSMF L1 consensus PCR
Bouda et al [26] 2000 29/34 85.2 Hyperplasia dysplasia Nested consensus PCR
Ha et al [21] 2002 1/102 1.0 Dysplasia Quantitative PCR
Ostwald et al [64] 2003 72/118 22.2 Oral Leukoplakia PCR/Southern blot hybridization
65/118 15.4 OLP
Lo Muzio et al [92] 2004 6/7 85.7 Oral leukoplakia Nested PCR, IHC
Campisi et al [65] 2004 68/139 17.6 Oral Leukoplakia PCR
71/139 19.7 OLP
Chen et al [67] 2006 12/23 52.6 OSMF PCR
Furrer et al [63] 2006 9/22 41 Potentially malignant and malignant head and neck 
lesions
PCR- Southern Blot
Giovannelli et al [93] 2006 50/116 22 Oral leukoplakia PCR
Bagan et al [62] 2007 0/13 0 Proliferative verrucous leukoplakia PCR
Luo et al [66] 2007 14/46 30.4 Pre-cancerous lesion Nested PCR, gene-chip arraysHead & Neck Oncology 2009, 1:22 http://www.headandneckoncology.org/content/1/1/22
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using highly sensitive molecular techniques like PCR/
Southern blot hybridization and reported that 22.2% oral
leukoplakias (OL) and 15.4% oral lichen planus (OLP)
lesions were positive in HPV DNA [64]. Campisi et al
studied the prevalence of HPV infection in OL and OLP in
comparison with healthy oral mucosa and reported that
HPV DNA was found in 17.6% of OL and in 19.7% of
OLP [65]. Luo et al reported that prevalence of HPV was
30.4% in precancerous lesions through nested PCR and
gene-chip arrays [66]. (Table 2)
Recently, a study was conducted by the author's group
with the aim to analyze the high-risk HPV DNA in oral
submucous fibrosis (OSMF) and to determine the role of
HPV infections. 105 cases, 33(31.4%) patients were posi-
tive for high risk HPV, while 72 (68.6%) were negative.
On correlating HPV with histopathological grading,
7(29.1%) patients of grade I, 11(28.9%) of grade II and
15(34.8%) of grade III OSMF were positive. While corre-
lating addiction habits with HPV, 18 (34.6%) areca nut
chewers were positive and showed a significant p value
(<0.05). The results showed that the level of agreement
between the HPV and koilocytosis was moderate, with a
Cohen kappa value of 0.524 (95% confidence interval
[CI]. 0.3406 to 0.7081). The sensitivity of the hybrid cap-
ture test vis-à-vis presence of koilocytosis was 59% (95%
CI: 0.4427 – 0.7363) and specificity was 91% (95% CI:
0.8102 – 0.9714) while the positive predictive value was
84% (95% CI: 0.6810 – 0.9489) and negative predictive
value was 73% (95% CI: 0.6190 – 0.8330 (Unpublished
data). Chen et al reported the positivity of HPV16 as
52.6% and HPV 18 as 25% in OSMF by the PCR method
[67]. Vidal et al reported 72.5% negative for low and high
risk HPV DNA, 22.5% positive for low and high risk HPV
DNA, 2.5% positive for low risk HPV DNA and 2.5% pos-
itive for high risk HPV DNA in 40 oral carcinoma cases by
the Hybrid Capture technique [68].
Prevalence of HPV in malignant lesions of the Head and 
neck
Human papillomavirus especially the high-risk (HR)
types (16 and 18), are widely recognized in the promotion
of tumorigenesis in the uterine cervical squamous cell car-
cinoma [18]. High-risk HPV are predominantly found in
OSCC and may play a role in its progression, while low-
risk sub types are usually associated with oral precancer-
ous lesions. Koppikar et al studied the HPV DNA in oral
carcinoma by PCR amplification and reported that HPV
could contribute to carcinogenesis [69].
D'Costa et al suggested that HPV 16 plays a direct role in
a certain populations of oral cancers whereas in a subpop-
ulation, HPV16 infection may be vital in the early events
associated with development of potentially oral lesion to
malignancy [70]. Mishra et al reported that involvement
of p65 in HPV infected oral cancer may be linked to
improved differentiation and better prognosis of the dis-
ease [71]. König et al suggested that over expression of
p16 has been demonstrated to be strongly related to the
presence of HPV16, 18. HNSCC has been shown to be
associated with HPV infection [72]. Muenscher et al
reported that the patients with no history of tobacco and/
or alcohol consumption may also suffer from the laryn-
geal malignancy. There may be several factors such as indi-
vidual predisposition, radiation, gastroesophageal reflux,
viral infection, dietary factors and environmental influ-
ences [73]. The presence of HPV infection in 35.5% of
their cases suggests a possible role in the etiology of laryn-
geal squamous cell carcinoma (LSCC) and supports the
role of high-risk types of HPV (16, 18 and 33) in its etiol-
ogy. HPV infection is not likely to influence survival rates
as an independent prognostic factor in patients with
laryngeal cancer [74]. Von et al suggested that the broad-
spectrum PCR is a reliable method for detection of HPV-
DNA [75].
Torrente et al reported that HPV DNA was found in 32%
of laryngeal carcinoma biopsies. The genotypes identified
were high-risk types, the most frequent being HPV 16.
Viral DNA was integrated into the host genome (genotype
HPV 16), providing supporting evidence for a role of HPV
in the carcinogenic pathway of laryngeal squamous cell
carcinoma [76]. Montaldo et al reported that only two
HPV genotypes (HPV 16 and HPV 31) were detected in
oral carcinoma. [77]. Agrawal et al recently reported that
HPV16-positive HNSCC cases were more likely than
HPV16-negative cases to have an oral HPV infection
detected before and after therapy, consistent with a behav-
ioral and/or biological disposition to infection [78]. Vari-
ous studies report the differences in the samples and
molecular assays utilized in malignant lesions. (Table 3)
[87-107].
HPV Vaccine
Currently, two prophylactic HPV vaccines, one is quadri-
valent 'Gardasil®' developed by Merck which protects
against HPV types 6, 11, 16 and 18 and another is bivalent
Cervarix® vaccine by Glaxo Smith Kline (GSK), protects
against HPV types 16 and 18. Prophylactic vaccinations
against high-risk HPV types eventually prevent a signifi-
cant number of carcinomas. Both vaccines are Virus like
particle (VLP) vaccines has been developed for primary
HPV vaccination and targets HPV 16 and 18, while
Gardasil, includes a standard alum adjuvant, also targets
HPV 6 and HPV 11. These vaccines are recommended for
vaccinating young adolescent girls at or before onset of
puberty. Gardasil® (Merck & Co, Bluebell, PA, USA) has
gained regulatory approval from U.S.-Food and Drug
Administration while Cervarix® (GlaxoSmithKline, Rixen-
sart, Belgium) has been approved in Australia and pend-Head & Neck Oncology 2009, 1:22 http://www.headandneckoncology.org/content/1/1/22
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Table 3: Prevalence of HPV in malignant lesions of the Head and neck
Study Year Types of Lesion Method Positive/cases % HPV type
Zeuss et al [87] 1991 SCC ISH 0/15 0 -
Holladay & Gerald [88] 1993 SCC PCR 7/37 19 16 & 18
Ostwald et al [94] 1994 SCC PCR/SB 16/26 62 16 (45%), 18 (35%) 6, 11 (15%)
Balaram et al [95] 1995 SCC PCR 67/91 74 6(13%), 11(20%), 16 (42%)
Cruz et al [96] 1996 SCC PCR 19/35 55 16(79%)
Wilczynski et al [97] 1998 SCC PCR 14/21 64 16(80%), 33(10%), 59(10%)
Bustos et al [98] 1999 SCC ISH 09/33 27 16
van Houten et al [99] 2001 HNSCC PCR & T-PCR 84 - High Risk HPV
Kojima et al [100] 2002 SCC PCR 35/53 66 38
Sugiyama et al [101] 2003 SCC PCR 30/86 35 16
Smith et al [31] 2004 SCC PCR 38/201 19 16
Koppikar et al [69] 2005 SCC PCR 6/102 6 16,18
Slebos et al [102] 2006 SCC RT-PCR 8/36 22 16
Luo et al [67] 2007 SCC PCR 11/51 73 -
Zhang et al [103] 2008 SCC ISH 10/30 33 -
Chuang et al [104] 2008 SCC RT-PCR 20/59 33.9 16
Simonato et al[105] 2008 SCC - 5/29 17.2 nested PCR
Richards et al [106] 2009 HNSCC LOH - - -
Gudleviciene et al [107] 2009 HNSCC - - - 16
Abbreviations: *PCR = Polymerase chain reaction, LOH = Loss of heterozygosity, RT-PCR = Real Time PCR, IHC = Immunohistochemistry, SB = 
Southern Blotting
Table 4: Quadrivalent and bivalent human papilloma virus vaccines
Types of Vaccine Types of HPV Manufacturer
L1 VLP (Gardasil™) base on recombinant yeast technology 6,11,16 and 18 Merck o., Inc. Whitehouse Station, NJ
L1 VLP (Cevarix™) base on recombinant buculovirus technology 16 and 18 Glaxo Smith Kline (GSK) Rixensart, BelgiumHead & Neck Oncology 2009, 1:22 http://www.headandneckoncology.org/content/1/1/22
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ing approval from regulatory agencies in the USA. (Table
4)
Giorgi Rossi et al reported that the identification of the
HPV as the necessary cause of cervical cancer introduced
two new tools for prevention: HPV DNA test and vaccine
and suggested that vaccine and screening interventions
must be integrated in a unique public health program and
screening should use less aggressive protocols, to be less
expensive and more sustainable and efficient [79]. Marra
et al suggested that a female-only vaccination programme
is more cost effective compared with the current cytology-
based pap smear screening programme, while the cost
effectiveness of a male and female vaccination pro-
gramme is generally less compared with female-only vac-
cination [80]. The Swedish National Board of Health and
Welfare (NBHW) decided that a vaccine that protects
against cervical cancer caused by HPV should be included
in the childhood vaccination directive as nationwide-pro-
gramme targeting 12-yearold girls from 2010 as a part of
the school-health programme. Currently, vaccination of
girls 13–18 years of age is covered by the public insurance
[81]. Adams et al suggested that prophylactic HPV vacci-
nation against HPV 16 and 18 has been shown to be
highly effective in preventing HPV related malignancy in
clinical trials. Newly introduced HPV vaccination pro-
gram in the UK and elsewhere are ultimately likely to
result in a further significant reduction in the incidence
and mortality of cervical cancer. These vaccination pro-
grams will be most effective in early adolescence when
prevalence of HPV infection is low. Consequently, vacci-
nation program in the UK have been initially targeted at
12 to 13-year olds.
In 2007, New South Wales, Australia implemented the
National human papillomavirus vaccination program,
which provides quadrivalent HPV vaccine free to all
women aged 12–26 years. In Australia, favorable esti-
mates of cost effectiveness have supported funding of a
'catch-up' programme to females up to 26 years of age.
[82]. Brotherton et al reported that the estimated rate of
anaphylaxis for quadrivalent HPV vaccine was signifi-
cantly higher (IR = 2.6/100 000 doses; 95% CI 1.0–5.3)
than identified in comparable school-based delivery of
other vaccines like conjugated meningococcal C vaccine
(IR = 0.1/100 000 doses; 95% CI 0.003–0.7) However,
overall rates were very low and managed appropriately
with no serious sequelae [83]. Lawrence et al reported that
two deaths were temporally associated with immuniza-
tion; however, there was no evidence to suggest a causal
association. They concluded that despite the low rate of
adverse events following immunization in Australia, the
passive surveillance system was sufficiently strong to
detect safety signals associated with vaccination. Further
studies are required before a clean chit can be given to its
safety [84].
The Rural Southern areas of North Carolina, USA have
accepted the HPV vaccine [85]. Goncalves et al reported
that the usefulness of the current HPV vaccine may be con-
sidered not only for the cervix but also for prevention of
HPV 18 anal infection among immunosuppressed indi-
viduals [86]. However in case of oral and oropharyngeal
carcinoma, a careful search did not reveal any literature in
relation to HPV vaccine.
Conclusion
HPV may play a role in the carcinogenesis of head and
neck malignancies. Molecular mechanisms have been
able to recognize its ability to disrupt key cellular ele-
ments responsible for the regulation of cell division and
apoptosis. Review of literature reveals that HPV may be a
risk factor for some head and neck malignancies, but not
in all cases. The prevalence of HPV in virus-related benign
lesions as well as malignancies has been confirmed by
many molecular techniques, among those, PCR is the
most sensitive method. For the confirmation of the role of
HPV in head and neck malignancies, large population
studies are necessary in an assortment of clinical settings.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
All authors read and approved the final manuscript.
Acknowledgements
The authors thank the Department of Science and Technology (DST), New 
Delhi for providing financial support (Grant No.SR/SO/HS-127/2007) to 
AKC for this study.
References
1. Flohr JK, Lee JH: Identical but different: mechanism of cancer
development and response to treatment for human papillo-
mavirus-related and non-related squamous cell cancer of the
head and neck.  S D Med 2008, 61(12):453-455.
2. American Cancer Society Inc  2008 [http://www.cancer.org/doc
root/STT/content/STT_1x_Cancer_Facts_and_Figures_2008.asp].
3. Mehrotra R, Pandya S, Chaudhary AK, Kumar M, Singh M: Preva-
lence of oral pre-malignant and malignant lesions at a terti-
ary level hospital in Allahabad, India.  Asian Pac J Cancer Prev
2008, 9(2):263-5.
4. Basu R, Mandal S, Ghosh A, Poddar TK: Role of tobacco in the
development of head and neck squamous cell carcinoma in
an eastern Indian population.  Asian Pac J Cancer Prev 2008,
9(3):381-86.
5. Strati K, Pitot HC, Lambert PF: Identification of biomarkers that
distinguish human papillomavirus (HPV)-positive versus
HPV-negative head and neck cancers in a mouse model.  Proc
Natl Acad Sci 2006, 103(38):14152-7.
6. Syrjänen S: Human papillomavirus (HPV) in head and neck
cancer.  J Clin Virol 2005, 32(1):59-66.
7. Scully C, Field JK, Tanzawa H: Genetic aberrations in oral or
head and neck squamous cell carcinoma (SCCHN): Carcino-
gen metabolism, DNA repair and cell cycle control.  Oral
Oncol 2000, 36:256-263.Head & Neck Oncology 2009, 1:22 http://www.headandneckoncology.org/content/1/1/22
Page 10 of 12
(page number not for citation purposes)
8. Pande P, Soni S, Kaur J, Agarwal S, Mathur M, Shukla NK, Ralhan R:
Prognostic factors in betel and tobacco related oral cancer.
Oral Oncol 2002, 38:491-499.
9. Girja KP, Sundharam BS, Krishnan PA, Devi CS: Biochemical
changes of saliva in tobacco chewers tobacco smokers, alco-
hol consumers, leukoplakia and oral cancer patients.  Indian J
Dent Res 2002, 13:102-107.
10. Vidal L, Gillison ML: Human papillomavirus in HNSCC: recog-
nition of a distinct disease type.  Hematol Oncol Clin North Am
2008, 22(6):1125-42.
11. Bosh FX, Lorincz A, Munoz N, et al.: The causal relation between
human papillomavirus and cervical cancer.  J Clin Pathol 2002,
55:244-265.
12. Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman
HT:  Presentation, treatment, and outcome of oral cavity
cancer: a National Cancer Data Base report.  Head Neck 2002,
24:165-180.
13. Syrjanen S: Human papillomavirus infections and oral tumors.
Med Microbiol Immunol 2003, 192:123-128.
14. Campisi G, Giovannelli L: Controversies surrounding Human
Papilloma Virus infection, head & neck vs oral cancer, impli-
cations for prophylaxis and treatment.  Head & Neck Oncology
2009, 1:8.
15. Smith EM, Ritchie JM, Yankowitz J, Wang D, Turek LP, Haugen TH:
HPV prevalence and concordance in the cervix and oral cav-
ity of pregnant women.  Infect Dis Obstet Gynecol 2004, 12:45-56.
16. Giraldo P, Goncalves AKS, Pereira SA, Barros-Mazon S, Gondo ML,
Witkin SS: Human papillomavirus in the oral mucosa of
women with genital human papillomavirus lesions.  Eur J
Obstet Gynecol Reprod Biol 2006, 126:104-106.
17. Syrjänen K, Syrjänen S, Lamberg M, Pyrhönen S, Nuutinen J: Morpho-
logical and immunohistochemical evidence suggesting
human papillomavirus (HPV) involvement in oral squamous
cell carcinogenesis.  Int J Oral Surg 1983, 12(6):418-24.
18. Zur Hausen H: Papillomavirus and cancer: from basic studies
to clinical application.  Nat Rev Cancer 2002, 2:342-350.
19. Erdmann J: Recent studies attempt to clarify relationship
between oral cancer and human papillomavirus.  J Natl Cancer
Inst 2003, 95:638-639.
20. Nair S, Pillai M: Human papillomavirus and disease mecha-
nisms: relevance to oral and cervical cancers.  Oral Dis 2005,
11:350-359.
21. Ha PK, Califano JA: The role of human papillomavirus in oral
carcinogenesis.  Oral Biol Med 2004, 15(4):188-196.
22. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L,
Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky
D: Evidence for a causal association between human papillo-
mavirus and a subset of head and neck cancers.  J Natl Cancer
Inst 2000, 92:709-20.
23. Zur HH: Papillomaviruses causing cancer: evasion from host-
cell control in early events in carcinogenesis.  J Natl Cancer Inst
2000, 92:690-698.
24. Zur Hausen H: Papillomavirus infections – a major cause of
human cancers.  Biochim Biophys Acta 1996, 1288:F55-F78.
25. Boyer SN, Wazer DE, Band V: E7 protein of human papilloma
virus-16 induces degradation of retinoblastoma protein
through the ubiquitin-proteasome pathway.  Cancer Res 1996,
56(20):4620-24.
26. Bouda M, Gorgoulis VG, Kastrinakis NG, Giannoudis A, Tsoli E, Dan-
assi-Afentaki D: "High risk" HPV types are frequently detected
in potentially malignant and malignant oral lesions, but not
in normal oral mucosa.  Mod Pathol 2000, 13(6):644-53.
27. Remmerbach TW, Brinckmann UG, Hemprich A, Chekol M, Kuhndel
K, Liebert UG: PCR detection of human papillomavirus of the
mucosa: comparison between MY09/11 and GP 5/6 primer
sets.  J Clin Virol 2004, 30:302-308.
28. Ragin CC, Modugno F, Gollin SM: The epidemiology and risk fac-
tors of head and neck cancer: a focus on human papillomavi-
rus.  J Dent Res 2007, 86(2):104-14.
29. Haddad R, Crum C, Chen Z, Krane J, Posner M, Li Y, Burk R: HPV16
transmission between a couple with HPV-related head and
neck cancer.  Oral Oncol 2008, 44(8):812-5.
30. Herrero R, Castellsague X, Pawlita M: Human papillomavirus and
oral cancer: the International Agency for Research on Can-
cer multicenter study.  J Natl Cancer Inst 2003, 95:1772-83.
31. Smith EM, Ritchie JM, Summersgill KF: Age, sexual behavior and
human papillomavirus infection in oral cavity and oropha-
ryngeal cancers.  Int J Cancer 2004, 108:766-72.
32. Braakhuis BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ,
Leemans CR, Brakenhoff RH: Genetic patterns in head and neck
cancers that contain or lack transcriptionally active human
papillomavirus.  J Natl Cancer Inst 2004, 96(13):978-80.
33. Chen X, Sturgis EM, El-Naggar AK, Wei Q, Li G: Combined effects
of the p53 codon 72 and p73 G4C14-to-A4T14 polymor-
phisms on the risk of HPV16-associated oral cancer in never-
smokers.  Carcinogenesis 2008, 29(11):2120-5.
34. Chen X, Sturgis EM, Etzel CJ, Wei Q, Li G: p73 G4C14-to-A4T14
polymorphism and risk of human papillomavirus-associated
squamous cell carcinoma of the oropharynx in never smok-
ers and never drinkers.  Cancer 2008, 113(12):3307-14.
35. Ji X, Sturgis EM, Zhao C, Etzel CJ, Wei Q, Li G: Association of p73
G4C14-to-A4T14 polymorphism with human papillomavirus
type 16 status in squamous cell carcinoma of the head and
neck in non-Hispanic whites.  Cancer 2009, 115(8):1660-8.
36. Li G, Sturgis EM, Wang LE, Chamberlain RM, Amos CI, Spitz MR, El-
Naggar AK, Hong WK, Wei Q: Association of a p73 exon 2
G4C14-to-A4T14 polymorphism with risk of squamous cell
carcinoma of the head and neck.  Carcinogenesis 2004,
25(10):1911-6.
37. Pintos J, Black MJ, Sadeghi N, Ghadirian P, Zeitouni AG, Viscidi RP,
Herrero R, Coutlee F, Franco EL: Human papillomavirus infec-
tion and oral cancer: a case-control study in Montreal, Can-
ada.  Oral Oncol 2008, 44:242-250.
38. Psyrri A, DiMaio D: Human papillomavirus in cervical and
head-and-neck cancer.  Nat Clin Pract Oncol 2008, 5:24-31.
39. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM: Human
papillomavirus positive squamous cell carcinoma of the
oropharynx: a radiosensitive subgroup of head and neck car-
cinoma.  Cancer 2001, 92:805-813.
40. de Villiers EM: Human pathogenic papillomavirus types: an
update.  Curr Top Microbiol Immunol 1994, 186:1-12.
41. Lee WT, Tubbs RR, Teker AM, Scharpf J, Strome M, Wood B, Lorenz
RR, Hunt J: Use of in situ hybridization to detect human pap-
illomavirus in head and neck squamous cell carcinoma
patients without a history of alcohol or tobacco use.  Arch
Pathol Lab Med 2008, 132(10):1653-6.
42. Frazer IH, Leonard JH, Schonrock J, Wright RG, Kearsley JH: HPV
DNA in oropharyngeal squamous cell cancers: comparison
of results from four DNA detection methods.  Pathology 1993,
25:138-143.
43. Kay P, Meehan K, Williamson AL: The use of nested polymerase
chain reaction and restriction fragment length polymor-
phism for the detection and typing of mucosal human papil-
lomaviruses in samples containing low copy numbers of viral
DNA.  J Virol Methods 2002, 105:159-170.
44. Yeudall WA, Campo MS: Human papillomavirus DNA in biop-
sies of oral tissues.  J Gen Virol 1991, 72:173-176.
45. Tavares R, Passos M, Cavalcanti S, Pinheiro V, Rubinstein I: Con-
diloma genital em homens e soropositividade para HIV.  DST
J Bras 2000, 12(1):4-27.
46. Snijders PJ, Meijer CJ, Walboomers JM: Degenerate primers
based on highly conserved regions of amino acid sequence in
papillomaviruses can be used in a generalized polymerase
chain reaction to detect productive human papillomavirus
infection.  J Gen Virol.  1991, 72(Pt 11):2781-2786.
47. Tieben LM, ter Schegget J, Minnaar RP, Bouwes Bavinck JN, Berkhout
RJ, Vermeer BJ: Detection of cutaneous and genital HPV types
in clinical samples by PCR using consensus primers.  J Virol
Methods 1993, 42:265-279.
48. Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, Lo Muzio
L, Campisi G: HPV in oral squamous cell carcinoma vs. head
and neck squamous cell carcinoma biopsies: a meta-analysis
(1988–2007).  Ann Oncol 2008, 19:1681-1690.
49. Kreimer AR, Clifford GM, Boyle P, Franceschi S: Human papillo-
mavirus types in head and neck squamous cell carcinomas
worldwide: a systematic review.  Cancer Epidemiol Biomarkers Prev
2005, 14:467-475.
50. Vijver MJ Van de, He YD, van't Veer LJ: A gene-expression signa-
ture as a predictor of survival in breast cancer.  N Engl J Med
2002, 347:1999-2009.Head & Neck Oncology 2009, 1:22 http://www.headandneckoncology.org/content/1/1/22
Page 11 of 12
(page number not for citation purposes)
51. Kuo WP, Jenssen TK, Park PJ, Lingen MW, Hasina R, Ohno-Machado
L: Gene expression levels in different stages of progression in
oral squamous cell carcinoma.  Proc AMIA Symp.  2002:415-419.
52. Guo X, Lui WO, Qian CN: Identifying cancer-related genes in
nasopharyngeal carcinoma cell lines uding DNA and mRNA
expression profiling analyses.  Int J Oncology 2002, 21:1197-1204.
53. Ibrahim SO, Aarsaether N, Holsve MK: Gene expression profile in
oral squamous cell carcinomas and matching normal oral
mucosal tissues from black Africans and white Caucasians:
the case of the Sudan vs. Norway.  Oral Oncology 2003, 39:37-48.
54. Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA: Identification
of differentially expressed genes in HPV-positive and HPV-
negative oropharyngeal squamous cell carcinomas.  Eur J Can-
cer 2007, 43(2):415-432.
55. Kovalenko S, Lukashenko P, Romanovskaya A, Soldatski IL, Bakanov
SI, Pfister H, Gerein V: Distribution and density of CD1a+ and
CD83+ dendritic cells in HPV-associated laryngeal papillo-
mas.  Int J Pediatr Otorhinolaryngol 2009, 73(2):249-56.
56. Martins RH, Dias NH, Gregório EA, Marques MA, Silva MG, Candeias
JM: Laryngeal papillomatosis: morphological study by light
and electron microscopy of the HPV-6.  Braz J Otorhinolaryngol
2008, 74(4):539-43.
57. Förster G, Boltze C, Seidel J, Pawlita M, Müller A: Juvenile laryngeal
papillomatosis – immunisation with the polyvalent vaccine
gardasil.  Laryngorhinootologie 2008, 87(11):796-9.
58. DeVoti JA, Rosenthal DW, Wu R, Abramson AL, Steinberg BM, Bon-
agura VR: Immune dysregulation and tumor-associated gene
changes in recurrent respiratory papillomatosis: a paired
microarray analysis.  Mol Med 2008, 14(9–10):608-17.
59. Castro TP, Bussoloti Filho I: Prevalence of human papillomavi-
rus (HPV) in oral cavity and oropharynx.  Braz J Otorhinolaryngol
2006, 72(2):272-82.
60. Fischer M: Investigation of a broad-spectrum PCR assay for
human papillomaviruses in screening benign lesions of the
upper aerodigestive tract.  ORL J Otorhinolaryngol Relat Spec 2005,
67(4):237-41.
61. Hoffmann M, Kahn T, Goeroegh T, Lohrey C, Gottschlich S, Meyer J,
Rudert H, Maune S: Tracing human papillomavirus DNA in
nasal polyps by polymerase chain reaction.  Acta Otolaryngol
2000, 120(7):872-5.
62. Bagan JV, Jimenez Y, Murillo J, Gavaldá C, Poveda R, Scully C, Alberola
TM, Torres-Puente M, Pérez-Alonso M: Lack of association
between proliferative verrucous leukoplakia and human
papillomavirus infection.  J Oral Maxillofac Surg 2007, 65(1):46-9.
63. Furrer VE, Benitez MB, Furnes M, Lanfranchi HE, Modesti NM:
Biopsy vs. superficial scraping: detection of human papillo-
mavirus 6, 11, 16, and 18 in potentially malignant and malig-
nant oral lesions.  J Oral Pathol Med 2006, 35(6):338-44.
64. Ostwald C, Rutsatz K, Schweder J, Schmidt W, Gundlach K, Barten
M: Human papillomavirus 6/11, 16 and 18 in oral carcinomas
and benign oral lesions.  Med Microbiol Immunol 2003,
192(3):145-8.
65. Campisi G, Giovannelli L, Aricò P, Lama A, Di Liberto C, Ammatuna
P, D'Angelo M: HPV DNA in clinically different variants of oral
leukoplakia and lichen planus.  Oral Surg Oral Med Oral Pathol Oral
Radiol Endod 2004, 98(6):705-11.
66. Luo CW, Roan CH, Liu CJ: Human papilloma viruses in oral
squamous cell carcinoma and pre-cancerous lesions
detected by PCR-based gene-chip array.  Int J Oral Maxillofac
Surg 2007, 36(2):153-38.
67. Chen PC, Pan CC, Kuo CC, Lin CP: Risk of oral nonmalignant
lesion associated with human papillomavirus infection, betel
quid chewing, and cigarette smoking in Taiwan: An inte-
grated molecular and epidemiological study.  Arch Pathol Lab
Med 2006, 130(1):57-61.
68. Vidal A, Júnior A, Mello R, Brandão V, Rocha G, Taromaru E: HPV
detection in oral carcinomas.  J Bras Patol Med Lab 2004,
40:21-26.
69. Koppikar P, De Villiiers FM, Mulherkar R: Identification of Human
papilloma viruses in tumour of the oral cancer in an Indian
Community.  Int J Cancer 2005, 113:946-50.
70. D'Costa J, Saranath D, Dedhia P, Sanghui V, Mehta AR: Detection of
HPV 16 genome in human oral cancer and potentially malig-
nant lesions from India.  Oral Oncol 1998, 34(5):413-20.
71. Mishra A, Bharti AC, Varghees P, Saluja D, Das BC: Differential
expression of NF-Kappa B family protein during oral carcino-
genesis: role of high HPV infection.  Int J Cancer 2006,
119:2840-50.
72. König F, Krekeler G, Hönig JF, Cordon-Cardo C, Fischer G, Korabi-
owska M: Relation between human papillomavirus positivity
and p16 expression in head and neck carcinomas – a tissue
microarray study.  Anticancer Res 2007, 27(1A):283-8.
73. Muenscher A, Feucht HH, Kutta H, Tesche S, Wenzel S: Integration
of human papilloma virus type 26 in laryngeal cancer of a
child.  Auris Nasus Larynx 2009, 36(2):232-4.
74. Morshed K, Polz-Dacewicz M, Szymañski M, Polz D: Short-frag-
ment PCR assay for highly sensitive broad-spectrum detec-
tion of human papillomaviruses in laryngeal squamous cell
carcinoma and normal mucosa: clinico-pathological evalua-
tion.  Eur Arch Otorhinolaryngol 2008, 265(1):89-96.
75. Von Winterfeld F, Fischer M: Broad-spectrum PCR assay for
detection of human papillomaviruses in oropharyngeal can-
cer.  Laryngorhinootologie 2007, 86(7):515-9.
76. Torrente MC, Ampuero S, Abud M, Ojeda JM: Molecular detection
and typing of human papillomavirus in laryngeal carcinoma
specimens.  Acta Otolaryngol 2005, 125(8):888-93.
77. Montaldo C, Mastinu A, Quartuccio M, Piras V, Denotti G, Pisano E,
Orrù G: Detection and genotyping of human papillomavirus
DNA in samples from healthy Sardinian patients: a prelimi-
nary study.  J Oral Pathol Med 2007, 36(8):482-7.
78. Agrawal Y, Koch WM, Xiao W, Westra WH, Trivett AL, Symer DE,
Gillison ML: Oral human papillomavirus infection before and
after treatment for human papillomavirus 16-positive and
human papillomavirus 16-negative head and neck squamous
cell carcinoma.  Clin Cancer Res 2008, 14(21):7143-50.
79. Giorgi Rossi P, Ronco G, Segnan N, Borgia P: Screening and vac-
cine: toward an integrated cervical cancer prevention pro-
gramme.  Epidemiol Prev 2008, 32(4–5):238-43.
80. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G: Effectiveness
and cost effectiveness of human papillomavirus vaccine: a
systematic review.  Pharmacoeconomics 2009, 27(2):127-47.
81. Tegnell A, Dillner J, Andrae B: Introduction of human papilloma-
virus (HPV) vaccination in Sweden.  Euro Surveill 2009,
14(6):191-19.
82. Adams M, Jasani B, Fiander A: Prophylactic HPV vaccination for
women over 18 years of age.  Vaccine 2009, 27(26):3391-4.
83. Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Camp-
bell-Lloyd S, New South Wales Health HPV Adverse Events Panel:
Anaphylaxis following quadrivalent human papillomavirus
vaccination.  CMAJ.  2008, 79(6):525-533.
84. Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre PB:
Annual report: surveillance of adverse events following
immunization in Australia, 2007.  Commun Dis Intell 2008,
32(4):371-87.
85. Fazekas KI, Brewer NT, Smith JS: HPV vaccine acceptability in a
rural Southern area.  J Womens Health (Larchmt) 2008,
17(4):539-48.
86. Goncalves MA, Randi G, Arslan A, Villa LL, Burattini MN, Franceschi
S, Donadi EA, Massad E: HPV type infection in different ano-
genital sites among HIV-positive Brazilian women.  Infect
Agent Cancer 2008, 3(1):5.
87. Zeuss MS, Miller CS, White DK: In situ hybridization analysis of
human papillomavirus DNA in oral mucosal lesions.  Oral Surg
Oral Med Oral Pathol 1991, 71:714-720.
88. Holladay EB, Gerald WL: Viral gene detection in oral neoplasms
using the polymerase chain reaction.  Am J Clin Pathol 1993,
100:36-40.
89. Fouret P, Martin F, Flahault A, Saint-Guily JL: Human papillomavi-
rus infection in the malignant and premalignant head and
neck epithelium.  Diagn Mol Pathol 1995, 4:122-127.
90. Nielsen H, Norrild B, Vedtofte P, Praetorius F, Reibel J, Holmstrup P:
Human papillomavirus in oral premalignant lesions.  Eur J Can-
cer B Oral Oncol 1996, 32(B):264-270.
91. Wen S, Tsuji T, Li X, Mizugaki Y, Hayatsu Y, Shinozaki F: Detection
and analysis of human papillomavirus 16 and 18 homologous
DNA sequences in oral lesions.  Anticancer Res 1997, 17:307-311.
92. Lo Muzio L, Campisi G, Giovannelli L, Ammatuna P, Greco I, Staibano
S, Pannone G, De Rosa G, Di Liberto C, D'Angelo M: HPV DNA
and survivin expression in epithelial oral carcinogenesis: a
relationship?  Oral Oncol 2004, 40(7):736-41.
93. Giovannelli L, Campisi G, Colella G, Capra G, Di Liberto C, Caleca
MP, Matranga D, D'Angelo M, Lo Muzio L, Ammatuna P: Brushing ofPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Head & Neck Oncology 2009, 1:22 http://www.headandneckoncology.org/content/1/1/22
Page 12 of 12
(page number not for citation purposes)
oral mucosa for diagnosis of HPV infection in patients with
potentially malignant and malignant oral lesions.  Mol Diagn
Ther 2006, 10(1):49-55.
94. Ostwald C, Muller P, Barten M, Rutsatz K, Sonnenburg M, Milde-Lan-
gosch K: Human papillomavirus DNA in oral squamous cell
carcinomas and normal mucosa.  J Oral Pathol Med 1994,
23:220-225.
95. Balaram P, Nalinakumari KR, Abraham E, Balan A, Hareendran NK,
Bernard HU: Human papillomaviruses in 91 oral cancers from
Indian betel quid chewers – high prevalence and multiplicity
of infections.  Int J Cancer 1995, 61:450-4.
96. Cruz IB, Snijders PJ, Steenbergen RD, Meijer CJ, Snow GB, Walboom-
ers JM: Age-dependence of human papillomavirus DNA pres-
ence in oral squamous cell carcinomas.  Eur J Cancer B Oral
Oncol.  1996, 32B(1):55-62.
97. Wilczynski SP, Lin BT, Xie Y, Paz IB: Detection of human papillo-
mavirus DNA and oncoprotein overexpression are associ-
ated with distinct morphological patterns of tonsillar
squamous cell carcinoma.  Am J Pathol 1998, 152:145-156.
98. Bustos J, Gómez B: Characteristics of a macrophage culture
persistently infected with herpes simplex virus type 1.  Arch
Med Res 1999, 30(3):255-62.
99. Van Houten VM, Snijders PJ, Brekel MW van den: Biological evi-
dence that human papillomaviruses are etiologically
involved in a subgroup of head and neck squamous cell car-
cinomas.  Int J Cancer 2001, 93(2):232-5.
100. Kojima A, Maeda H, Sugita Y, Tanaka S, Kameyama Y: Human pap-
illomavirus type 38 infection in oral squamous cell carcino-
mas.  Oral Oncol 2002, 38(6):591-6.
101. Sugiyama M, Bhawal UK, Dohmen T, Ono S, Miyauchi M, Ishikawa T:
Detection of human papillomavirus-16 and HPV-18 DNA in
normal, dysplastic, and malignant oral epithelium.  Oral Surg
Oral Med Oral Pathol Oral Radiol Endod 2003, 95(5):594-600.
102. Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, Zhang X, et al.: Gene expres-
sion differences associated with human papillomavirus sta-
tus in head and neck squamous cell carcinoma.  Clin Cancer Res
2006, 12(31):701-9.
103. Zhang MQ, El-Mofty SK, Dávila RM: Detection of human papillo-
mavirus-related squamous cell carcinoma cytologically and
by in situ hybridization in fine-needle aspiration biopsies of
cervical metastasis: a tool for identifying the site of an occult
head and neck primary.  Cancer 2008, 114(2):118-23.
104. Chuang AY, Chuang TC, Chang S, Zhou S, Begum S: Presence of
HPV DNA in convalescent salivary rinses is an adverse prog-
nostic marker in head and neck squamous cell carcinoma.
Oral Oncol 2008, 44(10):915-9.
105. Simonato LE, Garcia JF, Sundefeld ML, Mattar NJ: Detection of HPV
in mouth floor squamous cell carcinoma and its correlation
with clinicopathologic variables, risk factors and survival.  J
Oral Pathol Med 2008, 37(10):593-8.
106. Richards KL, Zhang B, Baggerly KA, Colella S, Lang JC, Schuller DE,
Krahe R: Genome-wide hypomethylation in head and neck
cancer is more pronounced in HPV-negative tumors and is
associated with genomic instability.  PLoS One.  2009,
4(3):e4941.
107. Gudleviciene Z, Smailyte G, Mickonas A, Pikelis A: Prevalence of
human papillomavirus and other risk factors in Lithuanian
patients with head and neck cancer.  Oncology 2009,
76(3):205-8.